Industry "vulnerability" to private litigation is concern of FDA's Office of Enforcement.
Executive Summary
INDUSTRY "VULNERABILITY" TO PRIVATE LITIGATION IS CONCERN TO FDA, Enforcement Office Director Daniel Michels told a Regulatory Affairs Professionals Society meeting Feb. 28. Michels reported that his office received "in excess of 240 requests for testimony of FDA employees" in 1994 in "an increasing number of private suits being brought against your firms, between firms as well as corporate stockholder suits."